George A. Eldridge, SEE REMARKS at Aerovate Therapeutics, Inc. (AVTE), sold 29,356 shares at $25.24 ($736K) on 2024-03-11, disclosed to the SEC on 2024-03-11.
Scheduled sale ($736k) by SEE REMARKS under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $25.00 | 22,386 | $560K | 76.1% |
| 2 | $25.00 | 114 | $3K | 0.4% |
| 3 | $25.24 | 3,423 | $86K | 11.7% |
| 4 | $25.24 | 3,423 | $86K | 11.7% |
| 5 | $26.31 | 10 | $263 | 0.0% |
| Total | $25.06 avg | 29,356 |
| $736K |
| 100% |
| Filing → |
| AVTE | SELL | 2024-04-03 | $780K | — | Filing → |
| AVTE | SELL | 2024-03-14 | $204K | — | Filing → |
| AVTE | SELL | 2022-12-13 | $479K | — | Filing → |